IQ Capital

Activity from announced rounds

Activity in this selectionUnited Kingdom · Oct 23, 2026 · Jan 1, 2026
Rounds participated in
8
Confirmed lead rounds
1
6 roles undisclosed
New companies
8
First participation on record · 0 follow-on
Funding in participating rounds
$266.7M
8 disclosed · full round size, not this investor’s share

By stage

Series A4
Seed2
Series C+1
Undisclosed1

By primary sector

Biotech3
Climate tech2
Cybersecurity2
Industrial tech1

By country

United Kingdom8

Rounds

8 in this selection
Undecimal Bio

Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease.

$18MSeed
Lead
Mindgard

Mindgard helps enterprise security teams find and address vulnerabilities in AI models, applications and agents.

$30MSeries A
Participant
IMU Biosciences

Profiles human immune systems using multi-omic analysis and machine learning for disease research.

$53MSeries A
Role not disclosed
RevEng.AI

Provides binary-level AI analysis of compiled software to detect hidden vulnerabilities and supply chain threats

$15MSeries A
Role not disclosed
Imperagen

Uses quantum physics simulation and AI to engineer high-performance enzymes for pharma and industrial markets

£5MSeed
Role not disclosed
Nyobolt

Develops ultra-fast-charging battery systems for autonomous robots, physical AI applications, and AI data center power infrastructure

$60MSeries C
Role not disclosed
Rivan

Develops synthetic fuel infrastructure for domestic energy production

$34MUndisclosed
Role not disclosed
Isembard

Develops software to automate manufacturing of key component parts for industries

$50MSeries A
Role not disclosed